Breakthrough in Waldenstrom's Macroglobulinemia Treatment: Cellectar Biosciences Achieves Primary Endpoint in Pivotal Clinical Study.
Bioscience Company Achieves Promising Macroglobulinemia Treatment Results
Bioscience Company Achieves Promising…
Bioscience Company Achieves Promising Macroglobulinemia Treatment Results
Breakthrough in Waldenstrom's Macroglobulinemia Treatment: Cellectar Biosciences Achieves Primary Endpoint in Pivotal Clinical Study.